1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

Executive Decisions Roundup

 
• By Malcolm Spicer

Another Coca-Cola exec pops up at NBTY; Hussain helms Glaxo pharma globally; China TCM office veteran returns; T-Bird tabs Huang as COO; and Lee named Calif. DTSC director.

[NBTY Inc.] adds another former Coca-Cola Co. executive to its management as Brian Wynne becomes Americas markets head, working with President and CEO Steve Cahillane, also a Coca-Cola veteran. The vitamin and nutritional supplement manufacturer, marketer and retailer said Dec. 8 Wynne will start in January as president of NBTY Americas and CEO of its U.S. subsidiary, United States Nutrition Inc., with general management responsibility and profit and loss accountability for the Ronkonkoma, N.Y.-based firm’s Wholesale Brands in North and South America. Wynne is a 25-year consumer packaged goods industry veteran who most recently served as Coca-Cola’s senior VP Strategy, Franchise Relations & Transformation for North America. Cahillane left his post as president of Coca-Cola’s Americas division in December 2013 and in September took the helm of Carlyle Group-owned NBTY Also see "Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane" - Pink Sheet, 20 August, 2014..

Abbas Hussain, GlaxoSmithKline PLC‘s head of international pharmaceutical business, takes a new role as Global Pharmaceuticals head, in charge...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By Xu Hu

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.

BIOSECURE Act Returning, Privacy, Gain-of-Function Bills Coming, Senate Sponsor Says

 
• By Laura Helbling

Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

More from Asia

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 
• By Eliza Slawther

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By Xu Hu

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.